Seeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method
SLIM involves repeated biomarker assessments during both the lead-in and post-treatment periods. It minimizes between-subject variability and improves the precision of within-subject estimates. It is well suited for early-phase, short-duration trials. It is not suitable for cognitive tests or other outcomes prone to practice or placebo effects. SLIM design can be an alternative to the traditional parallel design by reducing required sample sizes, thereby lowering the recruitment burden.
Authors
- Gene L. Bowman (ORCID: https://orcid.org/0000-0003-0111-1565)
- Hiroko H. Dodge (ORCID: https://orcid.org/0000-0001-7290-8307)
- Liu Chen (ORCID: https://orcid.org/0000-0003-3366-0294)
- Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
- Chao‐Yi Wu (ORCID: https://orcid.org/0000-0002-2187-6509)
- Howard Feldman (ORCID: https://orcid.org/0000-0002-9258-4538)
- Steven Edward Arnold (ORCID: https://orcid.org/0000-0002-9487-415X)
Institutions
- University of Alabama at Birmingham (US)
- Massachusetts General Hospital (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Center for Pain and the Brain (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/alz.70787
- Citations
- 1
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 2.63